Condition (MeSH)
ACTH-Secreting Pituitary Adenoma
ClinicalTrials.gov lists 6 trials for ACTH-Secreting Pituitary Adenoma or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
4 of the 6 trials are tagged with ACTH-Secreting Pituitary Adenoma itself; the rest are tagged with a narrower condition beneath it.
When did ACTH-Secreting Pituitary Adenoma trials start? (6)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2023 | 1 |
| 2014 | 1 |
| 2011 | 1 |
| 2009 | 1 |
| 2007 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 6 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are ACTH-Secreting Pituitary Adenoma trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 1 |
| Not applicable | 1 |
| Observational | 2 |
How many ACTH-Secreting Pituitary Adenoma trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Completed | 1 |
| Terminated | 2 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most ACTH-Secreting Pituitary Adenoma trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 1 |
Which serious adverse events do ACTH-Secreting Pituitary Adenoma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Hyperglycaemia | 6 | 1 |
| Nausea | 4 | 1 |
| Hypoglycaemia | 3 | 1 |
| Vomiting | 3 | 1 |
| Abdominal pain | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover ACTH-Secreting Pituitary Adenoma? (20)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant. | Frontiers in endocrinology | 2021 | Yes |
| Letter to the Editor From Helene Lasolle and Gérald Raverot: "USP8 and TP53 Drivers Are Associated With CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors". | The Journal of clinical endocrinology and metabolism | 2021 | Yes |
| CRH stimulation improves <sup>18</sup>F-FDG-PET detection of pituitary adenomas in Cushing's disease. | Endocrine | 2019 | Yes |
| Postoperative Diabetes Insipidus and Hyponatremia in Children after Transsphenoidal Surgery for Adrenocorticotropin Hormone and Growth Hormone Secreting Adenomas. | The Journal of pediatrics | 2018 | Yes |
| Histone Deacetylase Inhibitor SAHA Is a Promising Treatment of Cushing Disease. | The Journal of clinical endocrinology and metabolism | 2017 | Yes |
Showing 5 of 20 publications.
Prevalence (2)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Cushing disease | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Unspecified |
| Cushing disease | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Unspecified |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: rare-disease identity.
Not computed for conditions with fewer than 10 trials: drugs tested.